Payment overview · 2025
General Payments
$1,790.87
106 reported records · 20 companies
Healthcare provider profile · identity verified
Anna H Zezon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · TEANECK, NJ · NPI 1871866632
Verified facts
What the public records show
CMS Open Payments records show Anna H Zezon, M.D. received $1,790.87 in general payments during 2025 across 106 reported records.
Amgen Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Teriparatide.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $296.52 | 16.6% | 19 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $257.71 | 14.4% | 19 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $249.15 | 13.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $242.77 | 13.6% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $119.00 | 6.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $99.35 | 5.5% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $93.61 | 5.2% | 6 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $67.97 | 3.8% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $63.58 | 3.5% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $52.42 | 2.9% | 3 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $37.37 | 2.1% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $36.51 | 2.0% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $36.10 | 2.0% | 2 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $33.17 | 1.9% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $21.43 | 1.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.65 | 1.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $18.64 | 1.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.71 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.68 | 0.9% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,721.93 | 102 |
| Education | $68.94 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $231.35 | 11 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $177.92 | 10 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $155.62 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $119.49 | 7 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $119.00 | 5 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $93.61 | 6 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $87.15 | 6 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $85.29 | 5 | 2025 |
Source payment records
|
|||||
| SOVUNA Normalized: sovuna |
Drug | ANI Pharmaceuticals, Inc. | $79.79 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $67.97 | 3 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $63.58 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $53.99 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $52.42 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $51.20 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TERIPARATIDE teriparatide |
2025 | Teriparatide | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 88 | 26 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 84 | 29 |
| Enbrel Sureclick | Etanercept | 56 | suppressed |
| Methotrexate | Methotrexate Sodium | 53 | 19 |
| Meloxicam | Meloxicam | 25 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Rasuvo | Methotrexate/Pf | 15 | suppressed |
| Teriparatide | Teriparatide | 13 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,790.87 · 106 records | Amgen Inc. | ACTHAR, Actemra, Bimzelx, COSENTYX, ENBREL, EVENITY, HADLIMA, KEVZARA, KRYSTEXXA, LUPKYNIS, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORTHOVISC, OTEZLA, PEMGARDA, PURIFIED CORTROPHIN GEL, RINVOQ, SIMPONI ARIA, SKYRIZI, SOVUNA, TAVNEOS, TERIPARATIDE, TREMFYA, Tymlos, VEGZELMA, XELJANZ | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Teriparatide play in your treatment recommendations for me?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error